INSP
BULLISH
$55.11
Live
Inspire Medical Systems, Inc. · NYSE
Target $72.25
(+31.1%)
$48.3
52W Range
$163.35
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 29, 2026
Market cap
$1.59B
P/E
11.27
ROE
19.8%
Profit margin
15.9%
Debt/Equity
0.04
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
INSP exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an exceptionally clean balance sheet (Debt/Equity 0.04). While the stock has suffered a severe multi-year price collapse, it is currently trading almost exactly at its Graham Number ($54.84), suggesting it has reached a defensive valuation floor. The massive disconnect between the current price ($55.11) and the growth-based intrinsic value ($144.25), coupled with explosive earnings growth (308.4% YoY), presents a compelling value-growth opportunity. Despite bearish technicals and insider selling, the underlying profitability and liquidity metrics are superior to sector averages.
Key Strengths
Strong financial health indicated by Piotroski F-Score of 7/9
Exceptional gross margins (85.39%) and healthy ROE (19.77%)
Negligible debt levels (Debt/Equity 0.04) and high liquidity (Current Ratio 6.08)
Explosive earnings growth (308.4% YoY) with a consistent track record of beating estimates
Valuation is currently at a defensive floor (Price ≈ Graham Number)
Key Risks
Severe long-term price deterioration (5Y Change: -77.1%)
Bearish insider sentiment with recent selling activity
Strongly bearish technical trend (0/100 score)
Significant gap between current price and 52-week high ($163.35)
Dependence on continued high-growth trajectory to realize intrinsic value
AI Fair Value Estimate
Based on comprehensive analysis
$98.5
+78.7% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
56
Moderate
85
80
20
95
0
AI Verdict
Strong Fundamental Value Play
Key drivers: Piotroski Score, Earnings Growth, Low Debt, Graham Number Floor
Confidence
90%
Value
85/100
Ref P/E 11.27, Graham Number $54.84
Positives
- P/E of 11.27 is very low for healthcare
- Price is aligned with Graham Number
- Deep discount to intrinsic value
Watchpoints
- Forward P/E is higher than trailing P/E
Future
80/100
Ref Growth rates and Analyst Targets
Positives
- 308.4% Earnings Growth
- Consistent earnings surprises
- Strong analyst target price ($72.25)
Watchpoints
- Revenue growth (12.2%) is modest compared to earnings jump
Past
20/100
Ref Historical price performance
Positives
- Recent 1-month recovery (+9.3%)
Watchpoints
- Catastrophic 1Y, 3Y, and 5Y returns
- Price near 52-week lows
Health
95/100
Ref Piotroski F-Score and Debt/Equity
Positives
- Piotroski 7/9
- Debt/Equity 0.04
- Current Ratio 6.08
Watchpoints
- Altman Z-Score not provided
Dividend
0/100
Ref Yield 0%
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$55.11
Analyst Target
$72.25
Upside/Downside
+31.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for INSP and closest competitors.
Updated 2026-04-28
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
INSP
Inspire Medical Systems, Inc.
Primary
|
-77.1% | -79.4% | -65.1% | -28.6% | +9.3% | +5.9% |
|
ANIP
ANI Pharmaceuticals, Inc.
Peer
|
+113.5% | +73.9% | +14.7% | -27.9% | -7.5% | -4.8% |
|
IMCR
Immunocore Holdings plc
Peer
|
-3.6% | -38.5% | +20.3% | -4.2% | -4.5% | +0.7% |
|
NBTX
Nanobiotix S.A.
Peer
|
+91.8% | +705.8% | +855.9% | +12.8% | -6.4% | +5.6% |
|
AGIO
Agios Pharmaceuticals, Inc.
Peer
|
-46.7% | +21.9% | -10.4% | -24.3% | +0.5% | +1.4% |
INS
Inspire Medical Systems, Inc.
Primary
5Y
-77.1%
3Y
-79.4%
1Y
-65.1%
6M
-28.6%
1M
+9.3%
1W
+5.9%
ANI
ANI Pharmaceuticals, Inc.
Peer
5Y
+113.5%
3Y
+73.9%
1Y
+14.7%
6M
-27.9%
1M
-7.5%
1W
-4.8%
IMC
Immunocore Holdings plc
Peer
5Y
-3.6%
3Y
-38.5%
1Y
+20.3%
6M
-4.2%
1M
-4.5%
1W
+0.7%
NBT
Nanobiotix S.A.
Peer
5Y
+91.8%
3Y
+705.8%
1Y
+855.9%
6M
+12.8%
1M
-6.4%
1W
+5.6%
AGI
Agios Pharmaceuticals, Inc.
Peer
5Y
-46.7%
3Y
+21.9%
1Y
-10.4%
6M
-24.3%
1M
+0.5%
1W
+1.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
11.27
Forward P/E
21.32
PEG Ratio
N/A
P/B Ratio
2.02
P/S Ratio
1.74
EV/Revenue
1.43
EV/EBITDA
20.02
Market Cap
$1.59B
Profitability
Profit margins and return metrics
Profit Margin
15.95%
Operating Margin
17.14%
Gross Margin
85.39%
ROE
19.77%
ROA
3.71%
Growth
Revenue and earnings growth rates
Revenue Growth
+12.2%
Earnings Growth
+308.4%
Q/Q Revenue Growth
+12.25%
Q/Q Earnings Growth
+286.4%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.04
Low debt
Current Ratio
6.08
Strong
Quick Ratio
4.46
Excellent
Cash/Share
$10.78
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.3B
Gross Margin
86.6%
Op. Margin
17.1%
Net Margin
50.6%
Total Assets
$0.9B
Liabilities
$0.1B
Equity
$0.8B
Debt/Equity
0.16x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
80%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-04
$N/A
2026-02-11
$1.65
+142.1% surprise
2025-11-03
$0.38
+323.6% surprise
2025-08-04
$0.45
+120.3% surprise
Healthcare Sector Comparison
Comparing INSP against 564 companies in the Healthcare sector
(36 bullish, 168 neutral, 360 bearish)
P/E Ratio
11.27
This Stock
vs
74.29
Sector Avg
-84.8%
(Discount)
Return on Equity (ROE)
19.77%
This Stock
vs
-87.3%
Sector Avg
-122.7%
(Below Avg)
Profit Margin
15.95%
This Stock
vs
-16.1%
Sector Avg
-199.0%
(Weaker)
Debt to Equity
0.04
This Stock
vs
2.65
Sector Avg
-98.4%
(Less Debt)
Revenue Growth
12.2%
This Stock
vs
123.13%
Sector Avg
-90.1%
(Slower)
Current Ratio
6.08
This Stock
vs
4.46
Sector Avg
+36.1%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
INSP
Inspire Medical Systems, Inc.
|
BULLISH | $1.59B | 11.27 | 19.8% | 15.9% | $55.11 | |
|
ANIP
ANI Pharmaceuticals, Inc.
|
BEARISH | $1.58B | 21.23 | 16.2% | 8.9% | $70.49 | Compare |
|
IMCR
Immunocore Holdings plc
|
BEARISH | $1.57B | - | -9.6% | -8.9% | $31.05 | Compare |
|
NBTX
Nanobiotix S.A.
|
BEARISH | $1.54B | - | -% | -73.5% | $31.83 | Compare |
|
AGIO
Agios Pharmaceuticals, Inc.
|
BEARISH | $1.63B | - | -30.2% | -% | $27.85 | Compare |
INSP
Inspire Medical...
BULLISH
Mkt Cap
$1.6B
P/E
11.3
ROE
19.8%
Price
$55.11
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-15 | TANSEY CASEY M | Director | Stock Award | 308 | $16,038 |
| 2026-04-15 | BROADER SHELLEY G | Director | Stock Award | 342 | $17,808 |
| 2026-04-15 | ELLIS GARY LEE | Director | Stock Award | 518 | $26,972 |
| 2026-04-15 | MELENIKIOTOU GEORGIA | Director | Stock Award | 307 | $15,985 |
| 2026-02-20 | MANN MELISSA | Officer | Stock Award | 15,958 | - |
| 2026-02-20 | PHILLIPS BRYAN K | General Counsel | Stock Award | 26,757 | - |
| 2026-02-20 | HERBERT TIMOTHY P | Chief Executive Officer | Stock Award | 71,158 | - |
| 2026-02-20 | RONDONI JOHN | Officer | Stock Award | 18,358 | - |
| 2026-02-20 | WEATHERBY CARLTON | Officer | Stock Award | 35,791 | - |
| 2026-02-20 | KELLY JASON P | Officer | Stock Award | 15,958 | - |
| 2026-01-15 | TANSEY CASEY M | Director | Stock Award | 181 | $17,461 |
| 2026-01-15 | BROADER SHELLEY G | Director | Stock Award | 200 | $19,294 |
| 2026-01-15 | ELLIS GARY LEE | Director | Stock Award | 304 | $29,327 |
| 2026-01-15 | MELENIKIOTOU GEORGIA | Director | Stock Award | 180 | $17,365 |
| 2026-01-09 | RONDONI JOHN | Officer | Sale | 109 | $10,900 |
TANSEY CASEY M
Director
2026-04-15
308 shares
·
$16,038
BROADER SHELLEY G
Director
2026-04-15
342 shares
·
$17,808
ELLIS GARY LEE
Director
2026-04-15
518 shares
·
$26,972
MELENIKIOTOU GEORGIA
Director
2026-04-15
307 shares
·
$15,985
MANN MELISSA
Officer
2026-02-20
15,958 shares
PHILLIPS BRYAN K
General Counsel
2026-02-20
26,757 shares
HERBERT TIMOTHY P
Chief Executive Officer
2026-02-20
71,158 shares
RONDONI JOHN
Officer
2026-02-20
18,358 shares
WEATHERBY CARLTON
Officer
2026-02-20
35,791 shares
KELLY JASON P
Officer
2026-02-20
15,958 shares
TANSEY CASEY M
Director
2026-01-15
181 shares
·
$17,461
BROADER SHELLEY G
Director
2026-01-15
200 shares
·
$19,294
ELLIS GARY LEE
Director
2026-01-15
304 shares
·
$29,327
MELENIKIOTOU GEORGIA
Director
2026-01-15
180 shares
·
$17,365
RONDONI JOHN
Officer
2026-01-09
109 shares
·
$10,900
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
10-K
8-K
8-K
10-Q
INSP filed its 10-Q on November 3, 2025, providing updates on the company's business operations and financial condition. The filing includes detailed disclosures within the Management’s Discussion and Analysis and Risk Factors sections to outline current performance and potential operational risks.
8-K
8-K
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
12 analysts
Truist Securities
2026-04-15
Hold
Hold
Mizuho
2026-04-13
Outperform
Outperform
Stifel
2026-04-10
Buy
Buy
Evercore ISI Group
2026-04-06
Outperform
Outperform
Stifel
2026-03-05
Buy
Buy
Wolfe Research
2026-02-13
Outperform
Peer Perform
Jefferies
2026-02-12
Hold
Hold
RBC Capital
2026-02-12
Sector Perform
Sector Perform
Piper Sandler
2026-02-12
Overweight
Overweight
Truist Securities
2026-02-12
Hold
Hold
Past News Coverage
Recent headlines mentioning INSP from our newsroom.
Newest → oldest
No matching news yet.